Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience

Haploidentical-related donor (HID) hematopoietic stem cell transplantation (HSCT) has undergone significant advances in recent decades. Granulocyte colony-stimulating factor- and antithymocyte globulin-based protocols and post-transplantation cyclophosphamide-based regimens represent two of the current T-cell-replete protocols in HID HSCT. Recently, the optimization of several critical transplant techniques has further improved hematopoietic reconstitution, decreased the incidence of relapse and graft-versus-host disease after HID HSCT, and extended the application of HID HSCT to older patients and those with non-malignant hematologic disorders. Combining this approach with novel immunotherapy could further improve the efficacy and safety of HID HSCT. This review focuses on recent progress in the optimization of HID HSCT.